Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Iron Absorption in T2DM
NCT06629688Completed
- Sponsor
- Dubrava University Hospital
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Dubrava University Hospital. Primary endpoint: General objective: Effect on Intestinal Iron Absorption at 10 weeks. Started Nov 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06629688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06629688.